After two volatile years, FDA approvals in 2024 settled closer to their 10-year average. Will nominated commissioner Marty Makary shake things up, or maintain a steady ship?
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
References
Senior, M. Nat. Biotechnol. 42, 355–361 (2024).
Senior, M. Nat. Biotechnol. 41, 174–182 (2023).
Yiannopoulou, K. G., Anastasiou, A. I., Zachariou, V. & Pelidou, S. H. Biomedicines 7, 97 (2019).
Schmidt, M. E. et al. Neuropsychopharmacology 49, 1437–1447 (2024).
Shiga, T. Eur. Heart J. Suppl. 24, D11–D21 (2022). (Suppl. D).
Senior, M. Nat. Biotechnol. 42, 362–366 (2024).
Senior, M. Nat. Biotechnol. 42, 1331–1338 (2024).
Senior, M. Nat. Biotechnol. https://doi.org/10.1038/s41587-024-02506-7 (2024).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Senior, M. Fresh from the biotech pipeline: FDA approvals settle in 2024, but what next?. Nat Biotechnol 43, 159–165 (2025). https://doi.org/10.1038/s41587-025-02555-6
Published:
Issue date:
DOI: https://doi.org/10.1038/s41587-025-02555-6
